Pharmsynthez granted Orphan Drug Designation for Virexxa in the US
01-Mar-2011 -
Pharmsynthez announced that the United States Food and Drug Administration (FDA) has unanimously awarded Virexxa, OJSC Pharmsynthez’s treatment for hormonotherapy-resistant endometrial cancer (a malignant tumor of the female reproductive system), orphan drug designation.Virexxa is the first ...
cervical cancer
clinical trials
Orphan Drug Designation